AMENDMENT TO THE SPECIFICATION

Docket No.: CT-2640-NP

Please amend the Abstract as follows:

ABSTRACT

There is provided a method of treatment for disorders responsive to the modulation of KCNQ potassium channels by administering to a mammal in need thereof a therapeutically effective amount of a 2,4-disubstituted pyrimidine-5-carboxamide derivative of the Formula I

wherein R¹, R², R³, R⁴ and R⁵ are as defined below <u>in the specification</u>. The present invention also provides pharmaceutical compositions comprising openers or activators of the KCNQ potassium channels and especially to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine.